睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心上海市胸科医院Shanghai Chest Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07668752,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).

    入选标准第 3 条

  3. 5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.

    入选标准第 5 条

    5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.

    排除标准第 5 条

    6. Prior treatment with docetaxel as part of systemic therapy.

    排除标准第 6 条

    7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.

    排除标准第 7 条

    8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.

    排除标准第 8 条

  4. 6. At least one measurable target lesion according to RECIST version 1.1.

    入选标准第 6 条

  5. 2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.

    排除标准第 2 条

  6. 14. Pregnancy or breastfeeding.

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07668752,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Voluntary participation in the study and signed informed consent form (ICF).
  2. 2. Age ≥ 18 years at the time of signing the ICF; male or female.
  3. 3. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC).
  4. 4. Participants must provide adequate and qualified tumor tissue slides samples or agree to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation.
  5. 5. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy.
  6. 6. At least one measurable target lesion according to RECIST version 1.1.
  7. 7. Investigator assessed life expectancy ≥ 12 weeks.
  8. 8. Adequate organ function.
  9. 9. Ability to communicate well, comply with scheduled follow up visits, and adhere to protocol requirements.

排除标准:Exclusion Criteria:

  1. 1. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations.
  2. 2. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
  3. 3. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis.
  4. 4. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis.
  5. 5. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
  6. 6. Prior treatment with docetaxel as part of systemic therapy.
  7. 7. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
  8. 8. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
  9. 9. Clinically significant severe cardiovascular disease.
  10. 10. Stroke or other severe cerebrovascular disease within 6 months prior to randomization.
  11. 11. Major acute or chronic infectious disease.
  12. 12. Other poorly controlled systemic diseases.
  13. 13. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse.
  14. 14. Pregnancy or breastfeeding.
  15. 15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

引自 ClinicalTrials.gov, NCT07668752, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07668752,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07668752